FT News Briefing Novo Nordisk hits back at copycat drugs
101 snips
Feb 10, 2026 
Josh Franklin, U.S. banking editor focused on regulation and bank stability, and Patrick Temple-West, U.S. pharma correspondent tracking obesity and diabetes drugs, discuss Novo Nordisk’s lawsuit over alleged copycat weight-loss pills. They also cover gilts’ market moves, France’s central bank chief stepping down, and U.S. debate on boosting deposit insurance to prevent another SVB-style run.
AI Snips
Chapters
Transcript
Episode notes
Gilt Volatility Tied To UK Politics
- UK gilt yields spiked on fears over Keir Starmer's position after the Peter Mandelson appointment controversy.
- Cabinet support calmed markets, but local elections in May remain a key test.
Novo Nordisk Takes Legal Action
- Novo Nordisk sued Hims & Hers claiming patent infringement over copycat weight-loss drugs in the U.S..
- The lawsuit escalates an industry battle as Novo seeks to protect Ozempic and Wegovy amid heavy competition.
Hims & Hers Backed Down Quickly
- Hims & Hers initially announced a competing weight-loss pill and then backed down after backlash and legal pressure.
- Patrick Temple-West noted Hims & Hers said it would stop selling the pill but Novo still moved to court.